APA (7th ed.) Citation

Samyshkin, Y., Hertel, N., & Griebsch, I. (2011). PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients with Kras Wild-Type Tumours in the United Kingdom. Value in Health, A446. https://doi.org/10.1016/j.jval.2011.08.1171

Chicago Style (17th ed.) Citation

Samyshkin, Y., N. Hertel, and I. Griebsch. "PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients with Kras Wild-Type Tumours in the United Kingdom." Value in Health 2011: A446. https://doi.org/10.1016/j.jval.2011.08.1171.

MLA (9th ed.) Citation

Samyshkin, Y., et al. "PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients with Kras Wild-Type Tumours in the United Kingdom." Value in Health, 2011, p. A446, https://doi.org/10.1016/j.jval.2011.08.1171.